Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nuvalent, Inc. (NUVL : NSDQ)

• Company Description    Nuvalent Inc. is a biopharmaceutical company. It focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. The company's program pipeline includes ROS1-positive and ALK-positive NSCLC. Nuvalent Inc. is based in CAMBRIDGE, Mass. Number of Employees: 142

• Price / Volume Information    Yesterday's Closing Price: $100.59 Daily Weekly Monthly 20 Day Moving Average: 438,765 shares Shares Outstanding: 72.71 (millions) Market Capitalization: $7,313.57 (millions) Beta: 1.32 52 Week High: $112.88 52 Week Low: $55.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -5.87% -5.71% 12 Week 14.31% 12.46% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Broadway 14thFloor - Cambridge,MA 02142 USA ph: 857-357-7000 fax: - clister@nuvalent.com http://www.nuvalent.com

• General Corporate Information    Officers James R. Porter - Chief Executive Officer; President and Director Alexandra Balcom - Chief Financial Officer and Treasurer Deborah Miller - Chief Legal Officer and Secretary Grant Bogle - Director Emily Drabant Conley - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 670703107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 72.71 Most Recent Split Date: (:1) Beta: 1.32 Market Capitalization: $7,313.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.52 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-5.93 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.65 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -32.81% vs. Previous Quarter: -29.77% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - -38.84 06/30/25 - -32.58 ROA 12/31/25 - - 09/30/25 - -35.18 06/30/25 - -30.14 Current Ratio 12/31/25 - - 09/30/25 - 10.73 06/30/25 - 13.57 Quick Ratio 12/31/25 - - 09/30/25 - 10.73 06/30/25 - 13.57 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - 11.63 06/30/25 - 13.05 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©